Can Fibromyalgia Cause Depression? What the Evidence Actually Shows

Depression is the most common psychiatric condition found alongside fibromyalgia, and the relationship is not simply a matter of feeling low about being in pain. There are measurable biological pathways connecting the two, and there is longitudinal evidence that fibromyalgia comes first and depression follows.

For veterans, this direction matters. A veteran whose fibromyalgia is already service-connected — whether directly, or presumptively as a Gulf War veteran — may have a viable claim for major depressive disorder as a secondary condition. But this particular claim carries a specific legal complication that most claims do not, and understanding it in advance changes how the evidence should be assembled.

How often does depression occur with fibromyalgia?

Estimates vary widely depending on how depression is defined and measured. Reviews of the literature have found that somewhere between 6% and 35% of fibromyalgia patients meet criteria for a current major depressive episode, while 20% to 86% meet criteria for major depressive disorder at some point in their lives.⁵ More recent meta-analytic work puts current comorbid depression at roughly one in four patients, with more than half experiencing major depressive disorder at some point.⁶

That is an enormous range, and the range itself is informative. It reflects a genuine measurement problem: distinguishing clinical depression from the demoralization, fatigue, and sleep disturbance that fibromyalgia produces on its own is difficult, and different studies have drawn the line in different places. Any opinion that quotes a single tidy percentage is oversimplifying.

What is not in dispute is that the rate is far above the general population baseline, and that comorbid depression is associated with worse fibromyalgia outcomes — more pain, more disability, and poorer treatment response.⁷

Does the evidence show fibromyalgia leads to depression, or the reverse?

Both directions have support, but the evidence for fibromyalgia leading to depression is the stronger of the two.

A nationwide longitudinal study using Taiwan's National Health Insurance database followed 25,969 patients with fibromyalgia who had no psychiatric diagnosis at baseline. After adjustment for demographics and medical comorbidities, those patients had a substantially elevated risk of subsequently developing depression (hazard ratio 7.46, 95% CI 6.77–8.22). The same study ran the analysis in reverse and found that patients with depression had an elevated risk of subsequently developing fibromyalgia (hazard ratio 6.28, 95% CI 5.67–6.96).⁵ The authors concluded the relationship was bidirectional.

A 2025 prospective population study examined this more directly. Using the Lifelines cohort in the Netherlands, with more than 108,000 participants across two waves, researchers tested competing causal models for the relationship between internalizing disorders and functional disorders. When they narrowed to major depressive disorder and fibromyalgia specifically, the model that best fit the data was unidirectional: fibromyalgia predicted later major depressive disorder, but major depressive disorder did not predict later fibromyalgia.⁸

Two large studies, two somewhat different answers on directionality. That is worth stating plainly rather than papering over. The Taiwanese study used administrative diagnostic codes and identified both directions; the Dutch study used structured longitudinal measures and modeled direction of causation explicitly, finding support for only one. What both agree on is that fibromyalgia occurring first substantially raises the likelihood of subsequent depression.

For a veteran whose fibromyalgia was diagnosed years before any psychiatric diagnosis appeared, that is directly relevant evidence.

What connects them biologically?

This section is more technical. If you want the claims material, skip ahead.

The two conditions are not merely correlated in populations. They share specific neurobiological machinery, which is why the same medications treat both.

Shared serotonin and norepinephrine pathways

The descending inhibitory system — the brainstem circuitry that suppresses incoming pain signals at the spinal cord — runs largely on serotonin and norepinephrine.³ Those are the same neurotransmitter systems implicated in mood regulation.

In fibromyalgia, descending inhibition underperforms.⁴ And critically, that deficit is worse in fibromyalgia patients who also have depressive symptoms: a controlled study found the deficit of pain inhibition in fibromyalgia was more pronounced in patients with comorbid depression than in those without.⁹

This is one of the clearest mechanistic findings in the literature, because it does not just show that the two conditions co-occur. It shows that as depressive symptoms increase, the specific pain-suppression mechanism degrades further — a measurable amplification loop rather than two problems sitting side by side.

The clinical corollary is that duloxetine, milnacipran, and amitriptyline are used for fibromyalgia pain precisely because they act on these shared systems, and a systematic review and meta-analysis found antidepressants produce modest but real reductions in fibromyalgia pain, sleep disturbance, and depressed mood.¹⁰

Neuroinflammation

Positron emission tomography studies have shown elevated glial activation in the brains of fibromyalgia patients compared with controls.¹¹ Independently, inflammatory signaling is one of the better-supported biological mechanisms in depression, with peripheral and central inflammatory markers influencing mood, motivation, and reward processing.¹²

A shared inflammatory substrate offers a plausible route by which a chronic pain condition could produce, rather than merely accompany, a depressive illness. This work is recent and still being replicated; it should be described as an emerging mechanism, not established biology.

Sleep

Fibromyalgia disrupts sleep architecture directly — reduced slow-wave sleep, alpha intrusion into non-REM sleep.¹³ Non-restorative sleep is both a core feature of fibromyalgia and one of the strongest predictors of depression onset and recurrence. Sleep loss also impairs descending pain inhibition, closing the loop.¹³¹⁴

In practice, sleep is often where the fibromyalgia-to-depression sequence becomes visible in a veteran's records, because sleep complaints get documented early and repeatedly, long before anyone writes down a psychiatric diagnosis.

Stress-axis dysregulation

Both conditions are associated with altered hypothalamic–pituitary–adrenal axis function — flattened diurnal cortisol curves and abnormal feedback sensitivity rather than simple over- or under-production.¹⁵ The findings are heterogeneous in both conditions and are not diagnostic of anything at the individual level. They describe a shared physiology.

Functional and psychosocial loss

This mechanism is sometimes dismissed as "just" psychological. It should not be. Loss of occupational function, loss of physical capability, loss of independence, and withdrawal from valued roles and activities are among the best-documented risk factors for depression in any chronic illness.¹⁶ Chronic pain and depression are so reliably comorbid across conditions that the relationship has its own substantial literature.¹⁶

For veterans this often carries additional weight. A veteran whose identity was built around physical capability, and who can no longer do what they could do, is experiencing a specific and well-recognized form of loss.

Importantly, this psychosocial pathway is not a competing explanation to the biological ones. It operates alongside them, and in most patients both are running.

Does this mean fibromyalgia caused this veteran's depression?

Not automatically, and an opinion that asserts it without qualification is a weaker opinion.

Several alternative explanations deserve honest treatment in any credible analysis:

• Shared vulnerability. Genome-wide association work has identified overlapping genetic risk between major depression and fibromyalgia. A common underlying predisposition could produce both without either causing the other.
• Reverse causation. Depression is associated with increased risk of subsequently developing fibromyalgia in at least one large cohort.⁵ Where the depression predates the pain, the causal story runs the other way — or at least requires a different theory.
• A third condition driving both. PTSD, sleep apnea, hypothyroidism, and chronic medication effects can each contribute to both pain and mood symptoms.
• Diagnostic overlap. Fatigue, poor sleep, and concentration difficulty are diagnostic criteria for major depressive disorder and are also core fibromyalgia symptoms. A depression score can be inflated by fibromyalgia symptoms that are not depressive in origin.

What strengthens a causal inference in an individual case is the ordinary set of considerations clinicians use everywhere: documented temporal sequence, a plausible mechanism, dose–response (worsening pain and function tracking with worsening mood), and coherence with the independent physiology.

A precise opinion states that fibromyalgia is a well-supported contributing cause of depression in some patients, then argues from that veteran's actual chronology and records — not from population data alone.

What is the pyramiding problem, and why does it matter here?

This is the complication specific to this claim, and it is the one most often missed.

Diagnostic Code 5025, which rates fibromyalgia, describes the condition as widespread musculoskeletal pain and tender points "with or without associated fatigue, sleep disturbance, stiffness, paresthesias, headache, irritable bowel symptoms, depression, anxiety, or Raynaud's-like symptoms." 38 C.F.R. § 4.71a.

Depression is named in the rating code itself, as an associated feature of fibromyalgia.

That matters because of 38 C.F.R. § 4.14, the rule against pyramiding, which prohibits evaluating the same disabling manifestation under multiple diagnostic codes. If the depression is nothing more than the depressed mood already contemplated by DC 5025, an argument exists that it is already compensated within the fibromyalgia evaluation.

The counterweight is equally established. Separate evaluations are permitted where the symptomatology is distinct and not duplicative or overlapping. Esteban v. Brown, 6 Vet. App. 259 (1994). And the Federal Circuit has addressed this in the mental health context specifically, recognizing that two conditions may be separately evaluated where they produce distinct symptomatology, while the anti-pyramiding rule bars separate evaluations for the same manifestations. Amberman v. Shinseki, 570 F.3d 1377 (Fed. Cir. 2009).

The practical implication is that this claim turns on differentiation. A useful psychiatric opinion in this setting does not simply establish that depression exists and that fibromyalgia is service-connected. It establishes that the veteran has a distinct DSM-5 major depressive disorder with manifestations that go beyond the "depression" contemplated as an associated feature of fibromyalgia — for example, anhedonia, worthlessness or excessive guilt, psychomotor change, hopelessness, or suicidal ideation — and it identifies which functional impairments arise from the mood disorder rather than from pain.

This is precisely the kind of distinction a physician who evaluates and treats mental disorders is positioned to make, and precisely the kind that a one-paragraph letter cannot.

What does a psychiatric assessment actually contribute?

Diagnostic precision. Major depressive disorder is not the only possibility. Persistent depressive disorder, adjustment disorder with depressed mood, and depressive disorder due to another medical condition are all distinct DSM-5 diagnoses with different implications. So is depression secondary to a different service-connected condition — sleep apnea, chronic pain from a musculoskeletal injury, or PTSD. Getting the diagnosis right precedes everything else.

Differentiation from fibromyalgia's own symptoms. Separating the depressive illness from the fatigue, sleep disturbance, and cognitive complaints that fibromyalgia generates independently. This is the core analytic task in this claim, and it cuts both ways — it can support attribution, and it can show where attribution is not supportable.

Chronology. Reconstructing when pain symptoms began, when mood symptoms first appeared in the record, and in what order. Given that the longitudinal evidence supports fibromyalgia preceding depression, an accurate timeline is often the most persuasive single element.

Medication effects. This is unusually important here. A veteran taking duloxetine may be taking it for fibromyalgia pain, for depression, or for both, and the record often does not say which. Opioids, gabapentinoids, and sedating medications all affect mood, energy, and cognition. Some medications for other conditions carry depressive effects of their own. Untangling this requires someone who prescribes these drugs.

Functional impairment. The mental disorder rating criteria turn on occupational and social impairment, not on diagnosis or symptom count. Describing concretely what the veteran can no longer do — and attributing each limitation to the right condition — is what makes an assessment usable.

Differential and confounders. Ruling in or out sleep apnea, thyroid dysfunction, anemia, substance use, and other contributors that can mimic or worsen both conditions.

How can the VA connect depression to fibromyalgia?

There are three routes, and they are not interchangeable.

1. Secondary service connection — causation

Under 38 C.F.R. § 3.310(a), a disability that is proximately due to or the result of a service-connected disease or injury is service connected. This requires an individualized medical opinion addressing whether it is at least as likely as not (50% or greater probability) that the service-connected fibromyalgia caused the depressive disorder.

2. Secondary service connection — aggravation

Under 38 C.F.R. § 3.310(b) and Allen v. Brown, 7 Vet. App. 439 (1995), a non-service-connected condition chronically worsened by a service-connected disability may be compensated for the degree of worsening.

Aggravation is a separate and independent theory from causation, and it is frequently the better fit in this specific claim. Depression is common in the general population and often predates a fibromyalgia diagnosis. A veteran with a pre-existing depressive disorder that measurably worsened after fibromyalgia onset has a coherent aggravation theory even where a causation theory would fail. The two should be analyzed and stated separately, because they can succeed or fail independently.

3. Direct service connection

Under 38 C.F.R. § 3.303, depression may be directly connected where the evidence shows in-service onset or continuity of symptoms from service. This route does not depend on fibromyalgia at all, and it is sometimes overlooked when a veteran and their representative have anchored on the secondary theory.

A note for Gulf War veterans

If fibromyalgia is presumptively service connected under 38 U.S.C. § 1117 and 38 C.F.R. § 3.317, it can serve as the primary condition for a secondary claim. The regulation states that a qualifying chronic disability "shall be considered service connected for purposes of all laws of the United States." 38 C.F.R. § 3.317(a)(6).

That means a Gulf War veteran does not need to prove how their fibromyalgia arose in order to pursue depression as secondary to it. The presumptive route supplies the connection between fibromyalgia and service; the secondary opinion addresses only the relationship between fibromyalgia and depression. These are separate questions, and conflating them is a common source of confusion.

How does the VA rate depression?

Major depressive disorder is rated under 38 C.F.R. § 4.130, Diagnostic Code 9434, using the General Rating Formula for Mental Disorders. Ratings are assigned at 0%, 10%, 30%, 50%, 70%, or 100% based on the level of occupational and social impairment produced by the symptoms. The diagnosis itself must conform to the DSM-5. 38 C.F.R. § 4.125(a).

General Rating Formula for Mental Disorders — 38 C.F.R. § 4.130

Evaluation	Level of occupational and social impairment
100%	Total occupational and social impairment
70%	Deficiencies in most areas — work, school, family relations, judgment, thinking, or mood
50%	Reduced reliability and productivity
30%	Occasional decrease in work efficiency and intermittent periods of inability to perform occupational tasks
10%	Mild or transient symptoms, or symptoms controlled by continuous medication
0%	A diagnosed condition, but symptoms not severe enough to interfere with functioning or require continuous medication

Two points worth knowing:

All mental health diagnoses are evaluated together. Because every psychiatric diagnostic code cross-references the same general formula, a veteran with both PTSD and major depressive disorder generally receives one combined mental health evaluation rather than two, under § 4.14. Comorbidity is not irrelevant — the combined symptom burden and functional impairment can support a higher single evaluation — but it does not produce two separate mental health ratings.

The rating criteria have been proposed for revision but are not changed. The VA published a proposed rule in February 2022 (87 Fed. Reg. 8498) that would replace the General Rating Formula with a model scoring five functional domains — cognition, interpersonal relationships, task completion, navigating environments, and self-care — and would establish a 10% minimum evaluation for any service-connected mental disorder. That rule has drawn substantial comment and has not been finalized. The General Rating Formula in § 4.130 remains the operative criteria. Anyone telling veterans the new domain system is currently in effect is mistaken.

For advocates, VSOs, and family members

The pyramiding argument is the one to anticipate. More than in most secondary claims, expect the question of whether the depression is already contemplated within the fibromyalgia evaluation. Evidence that answers it in advance — documentation of distinctly depressive symptoms, and of impairment that pain alone does not explain — is worth gathering before filing rather than after.

Chronology beats assertion. Records showing fibromyalgia symptoms documented years before the first mention of mood symptoms do more work than any general statement about how the two conditions relate. Look for the first documented symptom, not the first documented diagnosis; both conditions are typically diagnosed long after they begin.

Ask which condition the medication is for. If a veteran is on duloxetine or amitriptyline, find out from the prescriber whether it was started for pain, for mood, or both. This detail comes up constantly and the record rarely answers it.

Lay statements are competent on observable change. A spouse or adult child can describe what they saw and when — the year the veteran stopped going to church, stopped seeing friends, stopped getting out of bed on bad days, started sleeping through the afternoon. That is factual observation, not medical opinion, and it establishes functional decline in a way that clinical notes often do not.

Function, not feelings. "He's depressed" is less useful than "he has missed four days of work a month for the past year, has not attended a family event since spring, and no longer manages the household finances he used to handle." The rating criteria measure occupational and social impairment; specific observations map onto them directly.

If someone you care about is struggling, treat it as urgent rather than as part of a claim. Depression in the setting of chronic pain is a serious medical condition, and it is treatable. Encourage them to speak with their own clinician. The Veterans Crisis Line is available 24 hours a day: dial 988 and press 1, or text 838255.

Where to go from here

If you are researching how a depressive disorder secondary to a chronic pain condition is documented in a medical opinion, our depression nexus letter page explains what that evaluation involves. Veterans whose fibromyalgia is not yet service connected may find the fibromyalgia nexus letter page more relevant as a starting point, since the primary condition generally has to be established first.

For anyone simply trying to understand their own situation, the mechanisms described above are worth raising with your own treating providers. Fibromyalgia and depression respond better when they are treated together than when either is treated in isolation.

Legal and regulatory authorities: 38 U.S.C. § 1117; 38 C.F.R. § 3.303; 38 C.F.R. § 3.310(a), (b); 38 C.F.R. § 3.317; 38 C.F.R. § 4.14; 38 C.F.R. § 4.71a, Diagnostic Code 5025; 38 C.F.R. § 4.125(a); 38 C.F.R. § 4.130, Diagnostic Code 9434; Allen v. Brown, 7 Vet. App. 439 (1995); Esteban v. Brown, 6 Vet. App. 259 (1994); Amberman v. Shinseki, 570 F.3d 1377 (Fed. Cir. 2009); Schedule for Rating Disabilities: Mental Disorders, 87 Fed. Reg. 8498 (proposed Feb. 15, 2022).

Bibliography

1. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114–129. ↩
2. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114(1–2):295–302. ↩
3. Chang MH, Hsu JW, Huang KL, et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. J Pain. 2015;16(9):895–902. ↩
4. Munipalli B, Chauhan M, Morris AM, et al. Recognizing and treating major depression in fibromyalgia: a narrative primer for the non-psychiatrist. J Prim Care Community Health. 2024;15:21501319241281221. ↩
5. Munipalli B, Allman ME, Chauhan M, et al. Depression: a modifiable risk factor for poor outcomes in fibromyalgia. J Prim Care Community Health. 2022;13:21501319221120738. ↩
6. Thomas NS, Neale MC, Kendler KS, van Loo HM, Gillespie NA. Prospective associations between major depressive disorder, generalized anxiety disorder, fibromyalgia, and myalgic encephalomyelitis/chronic fatigue syndrome. Psychol Med. 2025. doi:10.1017/S0033291725100603. ↩
7. de Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain. 2009;25(2):123–127. ↩
8. Häuser W, Wolfe F, Tölle T, Üçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297–307. ↩
9. Albrecht DS, Forsberg A, Sandström A, et al. Brain glial activation in fibromyalgia — a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72–83. ↩
10. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. ↩
11. Choy EH. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol. 2015;11(9):513–520. ↩
12. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2013;14(12):1539–1552. ↩
13. Martínez-Lavín M. Biology and therapy of fibromyalgia: stress, the stress response system, and fibromyalgia. Arthritis Res Ther. 2007;9(4):216. ↩
14. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445. ↩
15. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–1555. ↩
16. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329. ↩